Cingulate (Cingulate) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Cingulate Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cingulate is: No Data: Cannot be evaluated.

Competitive Comparison of Cingulate's Risk Assessment

For the Biotechnology subindustry, Cingulate's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cingulate's Risk Assessment falls into.

Cingulate (NAS:CING) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cingulate Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cingulate's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cingulate (Cingulate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 W. 47th Place, Kansas, KS, USA, 66205

Website

https://www.cingulate.com

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Executives

Jennifer L. Callahan	officer: Corporate Controller	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth	director, 10 percent owner	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer	director, 10 percent owner, officer: Chief Executive Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon	officer: EVP & General Counsel	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers	officer: EVP & Chief Operating Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum	director	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros	director	2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G	officer: EVP & Chief Financial Officer	C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher	director	275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy	director	2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva	officer: EVP & Chief Science Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams	officer: EVP & Chief Medical Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc	10 percent owner	1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205